November 23, 2025 • 4 mins
Welcome back to Ozempic Weight Loss Unlocked, the show where we break down the latest developments in weight loss medications and what they mean for your health. I'm your host, and today we're diving into some exciting new data and industry shifts that you need to hear about.
Let's start with what's happening right now in the weight loss medication world. A recent systematic review of over forty thousand adults found that semaglutide and tirzepatide significantly outperform older medications in achieving meaningful weight loss. In clinical trials, semaglutide resulted in a fourteen point nine percent reduction in body weight over sixty eight weeks, while tirzepatide led to a twenty point nine percent reduction. That's substantial progress compared to earlier options like liraglutide, which delivered only four to five percent weight loss.
But here's something important our listeners need to understand: clinical trial results don't always match real world outcomes. When researchers looked at actual users after one year, those taking semaglutide lost seven point seven percent of their body weight, and those on tirzepatide lost twelve point four percent. Why the difference? About fifty percent of patients discontinued treatment during that first year, and eighty percent took lower dosages than prescribed.
Speaking of usage, the numbers are staggering. Approximately one in eight American adults, or around twelve percent, have used a glucagon like peptide one medication at some point. Among people diagnosed with diabetes, that number jumps to forty three percent. The average age of users in the United Kingdom is forty four years old, with people aged forty to fifty nine making up more than half of all users.
Now let's talk money, because cost remains a major barrier. The monthly out of pocket cost for Ozempic in the United States can reach as high as twelve hundred dollars for uninsured individuals. This pricing has created a competitive marketplace. In November twenty twenty five, Pfizer won a bidding war with Novo Nordisk to acquire obesity drug developer Metsera, giving them injectable and oral glucagon like peptide one candidates expected to enter clinical trials soon.
But there's even more competition coming. Research indicates that several pharmaceutical companies including AstraZeneca, Zealand Pharma, Roche, and Amgen are expected to enter the glucagon like peptide one market with multiple drug launches planned between twenty twenty seven and twenty thirty two.
Interestingly, a new alternative is emerging. A medication called eloralintide, which targets a different hormone called amylin instead of glucagon like peptide one, showed promising results. In a phase two clinical trial with two hundred sixty three participants, those receiving eloralintide experienced average weight loss between nine and twenty percent after forty eight weeks, compared to only zero point four percent in the placebo group. Up to ninety percent of participants on eloralintide improved by at least one body mass index category, and the study showed improvements in cardiometabolic risk factors including waist circumference, blood pressure, and blood sugar management.
Our listeners should know that not everyone responds equally to these medications. Past studies show that as much as seventeen percent of glucagon like peptide one users may be non responders to the medication. This is why having multiple treatment options with different mechanisms of action matters so much.
One final note worth mentioning: the rise in glucagon like peptide one use has sparked increased demand for cosmetic surgeries to remove loose skin following significant weight loss. Procedures like arm lifts, thigh lifts, and tummy tucks have all seen increased demand.
Thank you so much for tuning in to Ozempic Weight Loss Unlocked. Please make sure to subscribe so you don't miss our next episode covering even more developments in this rapidly evolving space. This has been a Quiet Please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Let's start with what's happening right now in the weight loss medication world. A recent systematic review of over forty thousand adults found that semaglutide and tirzepatide significantly outperform older medications in achieving meaningful weight loss. In clinical trials, semaglutide resulted in a fourteen point nine percent reduction in body weight over sixty eight weeks, while tirzepatide led to a twenty point nine percent reduction. That's substantial progress compared to earlier options like liraglutide, which delivered only four to five percent weight loss.
But here's something important our listeners need to understand: clinical trial results don't always match real world outcomes. When researchers looked at actual users after one year, those taking semaglutide lost seven point seven percent of their body weight, and those on tirzepatide lost twelve point four percent. Why the difference? About fifty percent of patients discontinued treatment during that first year, and eighty percent took lower dosages than prescribed.
Speaking of usage, the numbers are staggering. Approximately one in eight American adults, or around twelve percent, have used a glucagon like peptide one medication at some point. Among people diagnosed with diabetes, that number jumps to forty three percent. The average age of users in the United Kingdom is forty four years old, with people aged forty to fifty nine making up more than half of all users.
Now let's talk money, because cost remains a major barrier. The monthly out of pocket cost for Ozempic in the United States can reach as high as twelve hundred dollars for uninsured individuals. This pricing has created a competitive marketplace. In November twenty twenty five, Pfizer won a bidding war with Novo Nordisk to acquire obesity drug developer Metsera, giving them injectable and oral glucagon like peptide one candidates expected to enter clinical trials soon.
But there's even more competition coming. Research indicates that several pharmaceutical companies including AstraZeneca, Zealand Pharma, Roche, and Amgen are expected to enter the glucagon like peptide one market with multiple drug launches planned between twenty twenty seven and twenty thirty two.
Interestingly, a new alternative is emerging. A medication called eloralintide, which targets a different hormone called amylin instead of glucagon like peptide one, showed promising results. In a phase two clinical trial with two hundred sixty three participants, those receiving eloralintide experienced average weight loss between nine and twenty percent after forty eight weeks, compared to only zero point four percent in the placebo group. Up to ninety percent of participants on eloralintide improved by at least one body mass index category, and the study showed improvements in cardiometabolic risk factors including waist circumference, blood pressure, and blood sugar management.
Our listeners should know that not everyone responds equally to these medications. Past studies show that as much as seventeen percent of glucagon like peptide one users may be non responders to the medication. This is why having multiple treatment options with different mechanisms of action matters so much.
One final note worth mentioning: the rise in glucagon like peptide one use has sparked increased demand for cosmetic surgeries to remove loose skin following significant weight loss. Procedures like arm lifts, thigh lifts, and tummy tucks have all seen increased demand.
Thank you so much for tuning in to Ozempic Weight Loss Unlocked. Please make sure to subscribe so you don't miss our next episode covering even more developments in this rapidly evolving space. This has been a Quiet Please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Welcome back to a zeenpic weight Loss Unlocked, the show
where we break down the latest developments and weight loss
medications and what they mean for your health. I'm your host,
and today we're diving into some exciting new data and
industry shifts that you need to hear about. Let's start
with what's happening right now in the weight loss medication world.
A recent systematic review of over forty thousand adults found
(00:21):
that semagluetide and tizzipathide significantly outperform older medications in achieving
meaningful weight loss. In clinical trials, summer glue tide resulted
in a fourteen point nine percent reduction in body weight
over sixty eight weeks, while tizzipathide led to a twenty
point nine percent reduction. That's substantial progress compared to earlier
options like liragluetide, which delivered only four to five percent
(00:45):
weight loss. But here's something important our listeners need to understand.
Clinical trial results don't always match real world outcomes. When
researchers look to actual users. After one year, those taking
semagluetide lost seven point seven percent of their body weight,
and those on teers are paid lost twelve point four percent.
(01:05):
Why the difference, about fifty percent of patients discontinued treatment
during that first year and eighty percent took lower dosages
than prescribed. Speaking of usage, the numbers are staggering. Approximately
one in eight American adults, or around twelve percent, have
used a glucagin like peptid one medication at some point.
(01:26):
Among people diagnosed with diabetes, that number jumps to four
by three percent. The average age of users in the
United Kingdom is forty four years old, with people aged
forty to fifty nine making up more than half of
(01:46):
all users. Now, let's talk money, because cost remains a
major barrier. The monthly out of pocket cost for ozebic
in the United States can reach as high as twelve
hundred dollars for uninsured individuals. This pricing has created a
competitive marketplace. In November twenty twenty five, Pfizer won a
(02:07):
bidding war with Novo Nordisk to acquire obesity drug developer Metzera,
giving them injectable and oral glucargan like peptide one candidates
expected to enter clinical trials soon. But there's even more
competition coming. Research indicates that several pharmaceutical companies including Astrozeneca, Zealand,
(02:35):
Farmer Roach and Amjin are expected to enter the glucagan
like peptide one market, with multiple drug launches planned between
twenty twenty seven and twenty thirty two. Interestingly, a new
alternative is emerging. A medication called ellurelintide, which targets a
different hormone called amelin instead of glucagan like peptide one,
(03:00):
showed promising results in a phase two clinical trial with
two hundred sixty three participants. Those receiving alloolintide experienced average
weight loss between nine and twenty per cent after forty
eight weeks, compared to only zero point four per cent
in the placebo group. Up to ninety per cent of
(03:21):
participants on a loorelin tide improved by at least one
body mass index category, and the study showed improvements in
cardiomatabolic risk factors including waste circumference, blood pressure, and blood
sugar management. All listeners should know that not everyone responds
equally to these medications. Past studies show that as much
as seventeen per cent of glucagin like putt BYED one
(03:43):
users it may be non responders to the medication. This
is why having multiple treatment options with different mechanisms of
action matters so much. One final note worth mentioning the
rise in glucagon like peptide one use has sparked increased
demand for cosmetic surgeries to remove loose skin following significant
weight loss. Procedures like armlifts, firelifts, and Tammy tucks have
(04:06):
all seen increased demand. Thank you so much for tuning
in to Ozepic Weight Loss Unlocked. Please make sure to
subscribe so you don't miss our next episode covering even
more developments in this rapidly evolving space. This has been
a quiet please production. For more check out Quiet Please
dot ai
Welcome back to a zeenpic weight Loss Unlocked, the show
where we break down the latest developments and weight loss
medications and what they mean for your health. I'm your host,
and today we're diving into some exciting new data and
industry shifts that you need to hear about. Let's start
with what's happening right now in the weight loss medication world.
A recent systematic review of over forty thousand adults found
(00:21):
that semagluetide and tizzipathide significantly outperform older medications in achieving
meaningful weight loss. In clinical trials, summer glue tide resulted
in a fourteen point nine percent reduction in body weight
over sixty eight weeks, while tizzipathide led to a twenty
point nine percent reduction. That's substantial progress compared to earlier
options like liragluetide, which delivered only four to five percent
(00:45):
weight loss. But here's something important our listeners need to understand.
Clinical trial results don't always match real world outcomes. When
researchers look to actual users. After one year, those taking
semagluetide lost seven point seven percent of their body weight,
and those on teers are paid lost twelve point four percent.
(01:05):
Why the difference, about fifty percent of patients discontinued treatment
during that first year and eighty percent took lower dosages
than prescribed. Speaking of usage, the numbers are staggering. Approximately
one in eight American adults, or around twelve percent, have
used a glucagin like peptid one medication at some point.
(01:26):
Among people diagnosed with diabetes, that number jumps to four
by three percent. The average age of users in the
United Kingdom is forty four years old, with people aged
forty to fifty nine making up more than half of
(01:46):
all users. Now, let's talk money, because cost remains a
major barrier. The monthly out of pocket cost for ozebic
in the United States can reach as high as twelve
hundred dollars for uninsured individuals. This pricing has created a
competitive marketplace. In November twenty twenty five, Pfizer won a
(02:07):
bidding war with Novo Nordisk to acquire obesity drug developer Metzera,
giving them injectable and oral glucargan like peptide one candidates
expected to enter clinical trials soon. But there's even more
competition coming. Research indicates that several pharmaceutical companies including Astrozeneca, Zealand,
(02:35):
Farmer Roach and Amjin are expected to enter the glucagan
like peptide one market, with multiple drug launches planned between
twenty twenty seven and twenty thirty two. Interestingly, a new
alternative is emerging. A medication called ellurelintide, which targets a
different hormone called amelin instead of glucagan like peptide one,
(03:00):
showed promising results in a phase two clinical trial with
two hundred sixty three participants. Those receiving alloolintide experienced average
weight loss between nine and twenty per cent after forty
eight weeks, compared to only zero point four per cent
in the placebo group. Up to ninety per cent of
(03:21):
participants on a loorelin tide improved by at least one
body mass index category, and the study showed improvements in
cardiomatabolic risk factors including waste circumference, blood pressure, and blood
sugar management. All listeners should know that not everyone responds
equally to these medications. Past studies show that as much
as seventeen per cent of glucagin like putt BYED one
(03:43):
users it may be non responders to the medication. This
is why having multiple treatment options with different mechanisms of
action matters so much. One final note worth mentioning the
rise in glucagon like peptide one use has sparked increased
demand for cosmetic surgeries to remove loose skin following significant
weight loss. Procedures like armlifts, firelifts, and Tammy tucks have
(04:06):
all seen increased demand. Thank you so much for tuning
in to Ozepic Weight Loss Unlocked. Please make sure to
subscribe so you don't miss our next episode covering even
more developments in this rapidly evolving space. This has been
a quiet please production. For more check out Quiet Please
dot ai
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
The Male Room with Dr. Jesse Mills
As Director of The Men’s Clinic at UCLA, Dr. Jesse Mills has spent his career helping men understand their bodies, their hormones, and their health. Now he’s bringing that expertise to The Male Room — a podcast where data-driven medicine meets common sense. Each episode separates fact from hype, science from snake oil, and gives men the tools to live longer, stronger, and happier lives. With candor, humor, and real-world experience from the exam room and the operating room, Dr. Mills breaks down the latest health headlines, dissects trends, and explains what actually works — and what doesn’t. Smart, straightforward, and entertaining, The Male Room is the show that helps men take charge of their health without the jargon.